January 7, 2008
Framingham Biotech Co. Looks For Partner
By Cory Hopkins
Framingham biotechnology company GI Co. Inc., a developer of treatments for gastrointestinal ailments, has retained San Francisco-based venture capitalists Burrill & Co. to assist the company in selecting a "transaction partner," according to a statement from GI.
GI currently has one protein treatment, its Intestinal Trefoil Factor, as a lead candidate for Phase II clinical trials. The therapy is designed to treat Oral Mucositis, a complication resulting from high dose chemotherapy or radiotherapy.
Burrill & Co. manages more than $950 million in its family of venture funds.
GI currently has one protein treatment, its Intestinal Trefoil Factor, as a lead candidate for Phase II clinical trials. The therapy is designed to treat Oral Mucositis, a complication resulting from high dose chemotherapy or radiotherapy.
Burrill & Co. manages more than $950 million in its family of venture funds.
WBJ Web Partners
Most Recent
Most Recent
0 Comments